Certolizumab pegol
- Generic Name
- Certolizumab pegol
- Brand Names
- Cimzia
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 428863-50-7
- Unique Ingredient Identifier
- UMD07X179E
- Background
Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent complement fixation and antibody-mediated cyt...
- Indication
Certolizumab pegol has been approved for several different conditions listed below:
...
- Associated Conditions
- Moderate to Severe Plaque Psoriasis, Moderately to Severely Active Rheumatoid Arthritis, Non-radiographic Axial Spondyloarthritis, Psoriatic Arthritis, Severe Crohn's Disease, Active Ankylosing spondylitis, Active Psoriatic arthritis, Moderate Crohn’s Disease, Moderate Psoriatic Arthritis, Moderate Rheumatoid arthritis, Severe Psoriatic Arthritis, Severe Rheumatoid arthritis
- Associated Therapies
- -
A Study to Assess the Pharmacokinetics of Certolizumab Pegol in Adults With Active Rheumatoid Arthritis
- First Posted Date
- 2021-02-05
- Last Posted Date
- 2024-02-12
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 33
- Registration Number
- NCT04740814
- Locations
- 🇺🇸
Ra0138 10025, Duncansville, Pennsylvania, United States
🇺🇸Ra0138 1016, Memphis, Tennessee, United States
🇺🇸Ra0138 1002, Covina, California, United States
A Study to Test Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Crohn's Disease
- Conditions
- Interventions
- First Posted Date
- 2020-11-25
- Last Posted Date
- 2021-06-23
- Lead Sponsor
- UCB Biopharma SRL
- Registration Number
- NCT04643483
Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis
- Conditions
- Interventions
- First Posted Date
- 2020-10-30
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- University of Erlangen-Nürnberg Medical School
- Target Recruit Count
- 270
- Registration Number
- NCT04610476
- Locations
- 🇩🇪
Universitätsklinikum Erlangen, Erlangen, Bavaria, Germany
A Study to Evaluate the Efficacy, Safety, and Drug Concentration of Certolizumab Pegol (CZP) in Children and Adolescent Study Participants With Moderate to Severe Chronic Plaque Psoriasis (PSO)
- Conditions
- Interventions
- First Posted Date
- 2019-10-11
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 150
- Registration Number
- NCT04123795
- Locations
- 🇺🇸
Ps0007 50214, Auburn, Alabama, United States
🇺🇸Ps0007 50175, Phoenix, Arizona, United States
🇺🇸Ps0007 50213, Anaheim, California, United States
A Study to Assess How Well Certolizumab Pegol Works in Patients With Moderate to Severe Plaque Psoriasis as Part of Routine Clinical Practice
- First Posted Date
- 2019-08-13
- Last Posted Date
- 2023-01-23
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 412
- Registration Number
- NCT04053881
- Locations
- 🇩🇪
Ps0026 529, Gladbeck, Germany
🇩🇪Ps0026 518, Karlsruhe, Germany
🇩🇪Ps0026 532, Bogen, Germany
Named Patient Program With Certolizumab Pegol in Adults Suffering From Rheumatoid Aarthritis (RA)
- Conditions
- First Posted Date
- 2018-06-18
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- UCB Biopharma SRL
- Registration Number
- NCT03559686
CUP Certolizumab Pegol (CDP-870) in Adults Suffering From Crohn's Disease (CD)
- Conditions
- First Posted Date
- 2018-06-18
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- UCB Biopharma SRL
- Registration Number
- NCT03559660
A Study to Test the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Patients With Active Ankylosing Spondylitis
- Conditions
- Interventions
- First Posted Date
- 2017-07-12
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 76
- Registration Number
- NCT03215277
- Locations
- 🇬🇷
As0013 406, Thessaloníki, Greece
🇵🇱As0013 708, Białystok, Poland
🇵🇱As0013 709, Kraków, Poland
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
- Conditions
- Interventions
- First Posted Date
- 2017-05-12
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- David Ware Branch
- Target Recruit Count
- 55
- Registration Number
- NCT03152058
- Locations
- 🇺🇸
Hospital for Special Surgery, New York, New York, United States
🇺🇸University of Utah, Salt Lake City, Utah, United States
🇨🇦TRIO Advancing Reproductive Care, Toronto, Ontario, Canada
Rheumatoid Arthritis Treatment After First Anti-TNF INvestiGation
- Conditions
- Interventions
- First Posted Date
- 2017-04-04
- Last Posted Date
- 2022-09-19
- Target Recruit Count
- 208
- Registration Number
- NCT03100253
- Locations
- 🇮🇹
Policlinico Sant'Orsola Malpighi, Bologna, Italy
🇮🇹Azienda Consorziale Ospedaliera Policlinico, Bari, Italy
🇮🇹Azienda Socio Sanitaria Territoriale - Papa Giovanni XXIII, Bergamo, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.